Stephen Glover

Company: ZyVersa Therapeutics
Job title: Chief Executive Officer
Seminars:
Strategic Prioritization of Inflammatory Indications: Navigating Risk, Reward & Clinical Feasibility 3:30 pm
Analyzing the trade-offs between orphan inflammatory indications vs larger markets with complex disease heterogeneity Reviewing how disease prevalence and competitive activity influences early pipeline decisions Unlocking real-world examples on how strategic indication shifts impact drug development opportunitiesRead more
day: Conference Day One PM